CSS
CRVO icon

Cubist Systematic Strategies’s CervoMed CRVO Stock Holding History

Cubist Systematic Strategies’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-990
Closed -$23.1K – 3173
2024
Q1 		$23.1K Buy
+990
New +$13.2K ﹤0.01% 3463

Other funds holding CRVO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's CRVO Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of CervoMed (CRVO) in Q2 2024, closing a stake of 990 shares — an estimated $23.1K sold.

Cubist Systematic Strategies first reported a position in CRVO in Q1 2024 and held it in 1 quarter. The position peaked at $23.1K in Q1 2024. 38 funds tracked by Wall St. Rank hold CRVO as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining CervoMed position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 990 CervoMed shares in Q2 2024, an estimated $23.1K.
  • Cubist Systematic Strategies first reported a position in CervoMed in Q1 2024 and held it in 1 quarter.
  • Cubist Systematic Strategies's CervoMed position peaked at $23.1K in Q1 2024.
  • 38 funds tracked by Wall St. Rank held CervoMed as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.